Drug Profile
ATX UV 3
Alternative Names: ATX-UV-3Latest Information Update: 17 Feb 2022
Price :
$50
*
At a glance
- Originator Apitope Technology
- Class Eye disorder therapies; Immunotherapies; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Uveitis
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Uveitis in United Kingdom
- 15 Mar 2019 ATX UV 3 is available for licensing as of 31 Oct 2018. https://apitope.com/
- 31 Oct 2018 Apitope has patent protection for the Apitope® discovery platform technology before October 2018 (Apitope website, October 2018)